Please login to the form below

Not currently logged in

Diabetes management underestimated in Asia

Boehringer/Lilly survey highlights need to improve patient education in India, China, Japan and South Korea

People in Asia with type 2 diabetes need more and improved information about their condition, according to a survey led by Boehringer Ingelheim and Lilly.

The survey, which involved 800 doctors in Japan, South Korea, India and China, found that more than three quarters of doctors surveyed believed more patient information is needed.

Respondents felt that the complexity of managing type 2 diabetes is underestimated, but that health outcomes and quality of life could be improved with high quality, structured patient education.

The survey also found that doctors were aware of the threat of heart disease and stroke to type 2 diabetes sufferers. A high proportion – 94 per cent – of those surveyed believed the management of cardiovascular risk influenced their decision when prescribing an oral anti-hyperglycaemic treatment.

A further important consideration when managing type 2 diabetes is the dosing schedule, the survey confirmed. Half of the respondents ranked 'number of doses per day' as the factor that influenced them the most when prescribing an oral anti-hyperglycaemic agent, in addition to the management of blood glucose.

“More than 60 per cent of the world's diabetes population lives in Asia and physicians treating type 2 diabetes in this region acknowledge that this is a complex condition,” said Professor Klaus Dugi, corporate senior vice president medicine, Boehringer Ingelheim.

“Despite the numerous challenges type 2 diabetes can present, results from this survey show that healthcare professionals in Asia are evaluating the full spectrum of available treatments, dosing regimens, risk factors and co-morbidities to achieve the best possible health outcomes for patients,” he said.

The survey echoed the results of a similar poll carried out by the two companies in Europe in September 2013.

Boehringer and Lilly have a diabetes partnership that includes co-marketing deal for the DPP-4 inhibitor Trajenta (linagliptin).

The drug is available in several markets worldwide, including the US and EU, and Boehringer's head of sales Allan Hillgrove recently confirmed to PMLiVE that the company has plans to launch the product in China through its partnership with Lilly.

Article by
Tara Craig

12th November 2013

From: Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...